Huda R M Rashdan
Overview
Explore the profile of Huda R M Rashdan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sayed Z, Hieba E, Batakoushy H, Rashdan H, Ismail E, Elkatlawy S, et al.
RSC Adv
. 2025 Jan;
15(2):1300.
PMID: 39816182
[This corrects the article DOI: 10.1039/D4RA06992G.].
2.
Sayed Z, Hieba E, Batakoushy H, Rashdan H, Ismail E, Elkatlawy S, et al.
RSC Adv
. 2024 Dec;
14(53):39297-39324.
PMID: 39670162
This work presents a review of the therapeutic modalities and approaches for cancer treatment. A brief overview of the traditional treatment routes is presented in the introduction together with their...
3.
El-Sayyad G, El-Khawaga A, Rashdan H
BMC Microbiol
. 2024 Nov;
24(1):453.
PMID: 39506685
Background: Although there are many uses for metal-organic framework (MOF) based nanocomposites, research shows that these materials have received a lot of interest in the field of water treatment, namely...
4.
Reheim M, Abdel Hafiz I, Reffat H, Abdel Rady H, Shehadi I, Rashdan H, et al.
Heliyon
. 2024 Jul;
10(13):e33160.
PMID: 39035494
In the present work, two hybrid series of pyrazole-clubbed pyrimidine and pyrazole-clubbed thiazole compounds from 4-acetyl-1,3-diphenyl-1-pyrazole-5(4)-ole were synthesized as novel antimicrobial agents. Their chemical structures were thoroughly elucidated in terms...
5.
Ibrahim A, Hassan A, Mosallam A, Khodairy A, Rashdan H, Abdelmonsef A
RSC Adv
. 2024 May;
14(24):17158-17169.
PMID: 38808238
This article contributes to the search for new therapeutic agents for treatment of diseases caused by bacterial pathogens. In this study, a new series of compounds incorporating numerous bioactive moieties...
6.
Rashdan H, Abdelrahman M, De Luca A, Mangini M
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256921
Aromatase inhibitors (AIs) show promising features as drugs to treat estrogen-responsive breast cancer as they block aromatase activity, the key enzyme in estrogen synthesis. The current AIs approved by the...
7.
Rashdan H, El-Sayyad G, Shehadi I, Abdelmonsef A
Molecules
. 2023 Nov;
28(22).
PMID: 38005213
In this investigation, 4-antipyrinecarboxaldhyde was reacted with methyl hydrazinecarbodithioate to afford the carbodithioate derivative . The as-prepared carbodithioate derivative is considered to be a key molecule for the preparation of...
8.
El-Naggar M, Rashdan H, Abdelmonsef A
ACS Omega
. 2023 Aug;
8(30):27216-27230.
PMID: 37546635
Four novel series of quinazolin-2,4-diones bearing five-, six-, and seven-membered heterocyclic moieties - (such as pyrazole, oxazole, pyrimidine, and azepines) through the 1,4-phenyl linkage were designed, synthesized, and evaluated in...
9.
Abdelraof M, Fikry M, Hashem A, El-Naggar M, Rashdan H
RSC Adv
. 2023 Jul;
13(30):20684-20697.
PMID: 37435382
For drug delivery applications, silica nanoemulsion encapsulated with organic compounds are becoming increasingly more desirable. Therefore, the emphasis of this research was on the synthesis of a new potent antifungal...
10.
Rashdan H, Okasha H, Salem M, Abd El-Hady B, Ekram B
Int J Biol Macromol
. 2023 Jun;
245:125420.
PMID: 37353115
Hepatitis C virus (HCV) is a major causative agent of chronic liver diseases including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Treatment of HCV has evolved from early interferon...